Skip to main content
. Author manuscript; available in PMC: 2017 Nov 29.
Published in final edited form as: Sci Signal. 2016 Nov 29;9(456):ra116. doi: 10.1126/scisignal.aaf3949

Fig. 5. Analysis of apoptosis and viability in BCP-ALL cell lines after treatment with pre-BCR pathway inhibitors.

Fig. 5

(A) Annexin V (FITC-conjugated) and 7-AAD labeling of 697 cells after 3 days of culture in the absence (autonomous) and presence of anti-VpreB Fabs or vincristine, as indicated. (B) 7-AAD and Annexin-V labeling of 697 cells treated for 3 days with a range of concentrations (0.1 to 100 μM) of tyrosine kinase inhibitors (BAY61-6306, dasatinib, tofacitinib) or inositol phosphatase (3AC). (C) 7-AAD and Annexin-V labeling of 697 cells treated for 3 days with or without a single dose (10 μM) of tyrosine kinase inhibitors (BAY61-6306, dasatinib, tofacitinib) in combination with increasing concentrations (0.1 to 100 ng/ml) of vincristine. (D) 7-AAD and Annexin-V labeling of 697 cells incubated for 3 days with or without 3AC (0.1 to 50 μM) in combination with increasing doses of vincristine (0.1 to 100 ng/ml). In all plots, the percentage of cells that were 7AAD+Annexin-V+ is plotted against increasing concentrations of vincristine or inhibitor and fit with a sigmoidal dose-response curve. All data were acquired by flow cytometric analysis of at least 10,000 events for each condition and are representative of xxx independent experiments.